

Appendix A. Antimicrobial susceptibility for MRSA bloodstream infection (England): 2015 to 2018

Year	Antimicrobials Tested		Proportion* %		
			Susceptible	Intermediate	Resistant
2015	Gentamicin	736	89	0	11
2015	Ciprofloxacin	750	29	1	70
2015	Vancomycin	709	100	0	0
2015	Teicoplanin	592	100	0	0
2015	Linezolid	625	100	0	0
2015	Erythromycin	529	47	0	53
2015	Rifampicin	766	97	1	2
2015	Mupirocin	701	93	2	5
2015	Fusidic Acid	744	83	1	17
2016	Gentamicin	718	89	0	11
2016	Ciprofloxacin	691	32	1	67
2016	Vancomycin	624	100	0	0
2016	Teicoplanin	556	99	0	1
2016	Linezolid	621	100	0	0
2016	Erythromycin	565	44	1	56
2016	Rifampicin	711	96	1	3
2016	Mupirocin	683	94	2	4
2016	Fusidic Acid	710	79	1	20
2017	Gentamicin	719	85	0	15
2017	Ciprofloxacin	670	32	2	66
2017	Vancomycin	633	100	0	0
2017	Teicoplanin	586	99	0	1
2017	Linezolid	646	100	0	0
2017	Erythromycin	662	45	0	55
2017	Rifampicin	685	96	0	3
2017	Mupirocin	685	94	2	4
2017	Fusidic Acid	710	77	0	22
2018	Gentamicin	763	85	0	15
2018	Ciprofloxacin	709	37	1	62
2018	Vancomycin	628	100	0	0
2018	Teicoplanin	569	100	0	0
2018	Linezolid	662	100	0	0
2018	Erythromycin	694	50	0	50
2018	Rifampicin	723	97	0	3
2018	Mupirocin	724	95	2	3
2018	Fusidic Acid	762	75	0	25